Temozolomide (TMZ) CAS 85622-93-1 Assay 99.0% ~ 101.0% API Factory High Purity
Ukubonelela ngeTemozolomide kunye neMidiya eNxulumeneyo:
I-Temozolomide CAS: 85622-93-1
4 (5)-Amino-5 (4)-Imidazolecarboxamide CAS: 360-97-4
5 (4)-Amino-4 (5)-Imidazolecarboxamide Hydrochloride CAS: 72-40-2
| Igama leMchiza | Temozolomide |
| Izithethantonye | 3,4-Dihydro-3-Methyl-4-Oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-Carboxamide |
| Inombolo yeCAS | 85622-93-1 |
| Inombolo yeCAT | RF-API29 |
| Ubume beStokhwe | Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni |
| Ifomula yeemolekyuli | I-C6H6N6O2 |
| Ubunzima beMolekyuli | 194.15 |
| Indawo yokunyibilika | NgoDisemba 212 ℃ |
| Uphawu | Ruifu Chemical |
| Into | Iinkcukacha |
| Imbonakalo | Umgubo oMhlophe ukuya kokuKhanya oPinki |
| Ukuchongwa | Ngo-IR, HPLC |
| Izinyibilikisi ezishiyekileyo | I-Dimethyl Sulphoxide ≤0.50% |
| Izinto ezinxulumeneyo | |
| Ukungacoceki kwe-AIC | ≤0.10% |
| Ukungacoceki Okukodwa | ≤0.10% |
| Phumla ukungcola okungaziwayo | ≤0.30% |
| Ukungcola ngokupheleleyo | ≤0.30% |
| Iintsimbi ezinzima | ≤10ppm |
| Ilahleko ekomisweni | ≤0.50% |
| Intsalela kwi-Ignition | ≤0.10% |
| Isivavanyi | 99.0% ~ 101.0% (HPLC kwisiseko esomisiweyo) |
| Umgangatho woVavanyo | Umgangatho woShishino |
| Ukusetyenziswa | I-Active Pharmaceutical ingredient (API) |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, igubu lekhadibhodi, 25kg/Igubu, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ekukhanyeni, ukufuma kunye nokuhlaselwa zizinambuzane.
I-Shanghai Ruifu Chemical Co., Ltd. ngumenzi ohamba phambili kunye nomthengisi weTemozolomide (CAS: 85622-93-1) kunye nomgangatho ophezulu.I-Temozolomide (TMZ) yi-agent yomlomo ye-alkylating esetyenziselwa ukuphatha i-Glioblastoma Multiforme (GBM) kunye ne-Astrocytomas, i-Metastatic Melanoma.
I-Temozolomide yinto yokuqala esebenzayo yomlomo-i-imidazole kunye ne-tetrazine-class ye-antiticancer ye-antiticancer yesizukulwana sesibini se-alkylating agent kunye nomsebenzi we-antitumor ngaphandle kokusebenza kwesibindi se-metabolic emva kokulawulwa komlomo.Ibonakala ngokungena lula ngomqobo wegazi-ingqondo, ukunyamezelana kakuhle kunye nokungabekwa phezulu kunye nezinye iziyobisi ezinobungozi, kunye nokuba nefuthe le-synergistic kunye ne-radiotherapy efanelekile ukunyanga ukuphindaphinda kwe-glioma enobungozi emva konyango oluqhelekileyo olufana ne-glioblastoma multiforme tumors okanye i-astrocytoma ewohlokayo.Lichiza lokuqala lonyango lwe-metastatic melanoma.
I-Temozolomide yayiye yaqulunqwa okokuqala yiCancer Research UK Group, kwaye emva koko idluliselwe kwiNkampani yeSchering-Plough (eUnited States) ukuze iphuhliswe.Inoveli yesakhiwo sekhemikhali kwaye iphuma kwi-4-imidazole derivative.Ngo-1999, kuye kwavunywa ukuba kungenwe kwimarike e-EU nase-US apho isalathiso esivunyelweyo e-United States ikakhulu sodidi lwesibini lonyango lwe-glioblastoma multiforme kunye ne-degenerative star gliomas kunye neempawu ezivunyiweyo ze-EU kunyango oluphuhlayo okanye olubuyisela umva i-glioblastoma multiforme. esele iphantsi konyango oluqhelekileyo.Ukusebenza kwe-temozolomide ekunyangeni i-glioblastoma multiforme kuye kwaqatshelwa ngakumbi eYurophu.
